Recent Quotes (30 days)

You have no recent quotes
chg | %

Cryosite Limited  

(Public, ASX:CTE)   Watch this stock  
Find more results for ASX: CTE
0.000 (0.00%)
Delayed:   10:49AM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.08 - 0.20
Open     -
Vol / Avg. 0.00/3,059.00
Mkt cap 4.69M
P/E 20.83
Div/yield 0.00/10.00
EPS 0.00
Shares 46.86M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -0.56% 2.21%
Operating margin -0.51% 3.29%
EBITD margin - 9.07%
Return on average assets -0.57% 2.31%
Return on average equity -1.70% 6.90%
Employees 34 -
CDP Score - -


13a Ferndell St
Lane Cove, NSW 2142
+61-2-88652000 (Phone)
+61-2-88652090 (Fax)

Website links


Cryosite Limited is a biotechnology and biologics logistics company. The Company is engaged in cryopreservation and expansion of mesenchymal stem cells (MSCs) from umbilical cord tissue. The Company operates through two segments: Individualised Consumer Biologics, and Scientific Processing and Logistics. The Individualised Consumer Biologics segment provides cord tissue MSC banking to parents, and specialized contract good manufacturing practice (GMP) manufacturing and associated consultancy services to therapeutic and regenerative medicine companies involved in the development and commercialization of technologies. The Scientific Processing and Logistics segment provides specialized commercial drug distribution. The Company also provides specialized bio-repository, clinical trials logistics, commercial drug distribution, contract cellular therapies manufacturing and associated consultancy services to commercial clients both within Australia and internationally.

Officers and directors

Mark Byrne Chief Executive Officer, Chief Financial Officer
Bryan Dulhunty Company Secretary
Stephen Roberts Non-Executive Chairman of the Board
Andrew John Kroger Non-Executive Director
Nicola J. Swift Non-Executive Director
Age: 52